About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

The following is a summary of “Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive ...

Poly (ADP-ribose) polymerase (PARP) inhibitors are used as maintenance therapy after completion of platinum-based ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median ...

智通财经APP获悉，阿斯利康 (AZN.US) 和默沙东 (MRK.US) 今日公布了3期临床试验OlympiA的长期结果。研究显示，PARP抑制剂Lynparza (olaparib，奥拉帕利)在携带种系BRCA突变 ...

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...

When Sue Vincent was diagnosed with advanced ovarian cancer, she was told she could have just months to live - until a ...

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) demonstrated sustained, clinically meaningful improvements in overall survival (OS), invasive disease-free survival (IDFS ...